FORM PTO-14 (REV. 7-80)	BIRAB	EMARKS				MENT D TRAD		ATTY. DOCKET NO. 200.1079CON4	SERIAL NO.: 10/056,348					
LIST OF PRIO	R ART	CITED B	Y APF	LICA	NT			APPLICANT(S): Ronald M. BURCH, et al.						
(Use several sl	neets if	necessa	ry)					FILING DATE: January 25, 2002	GROUP: 1639					
U.S. PATENT D									and the state of t					
*EXAMINER		DOCU	MENT	NUME	BER		•	DATE	NAME	CLASS	SUBCLASS FILING DATE IF APPROPRIATE			
	-AA									ACCOUNT OF THE PARTY OF THE PAR				
	AB	-	AND DESCRIPTION OF THE PERSONS	**************************************					The state of the s					
	AC				SOURCE OF	DECOMPOSION OF THE PERSON OF T		THE REAL PROPERTY.	SARAH S					
FOR CONTRACTENT DOCUMENTS														
		DOCUMENT NUMBER DATE							COUNTRY	CLASS	SUBCLASS	TRANSLA YES	NO	
·		THE REAL PROPERTY.	The state of the s		r					CONTROL OF THE PARTY OF THE PAR	000000	165	NU	
- MARION	AD	SORGE .					-					000000000		
THE REAL PROPERTY AND ADDRESS OF THE PERSON NAMED IN COLUMN TWO IS NOT THE PERSON NAMED IN COLUMN TWO IS NAMED IN COLUMN T	AĒ												DOGGEROOGGEROOGG	
	AF			L			<u> </u>	<u> </u>			<u> </u>	<u> </u>	!	
(0.1.)	OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)													
/S.L./	AG	Degner, Frank, et al., "Efficacy and Tolerability of Meloxicam in an Observational, Controlled Cohort Study in Patients with Rheumatic Disease", Clin Therapeutics (Nov 2000) 22: 400-410.												
	АН	Lanes, Stephan et al., "Baseline Risk of Gastrointestinal Disorders Among New Users of Meloxicam, Ibuprofen, Diclofenac, Naaproxen and Indomethacin", Pharmacoepidemiology and Drug Safety (2000) 9:113-117.												
Bosossooge	AI	Translation of Office Action dated November 1, 2001, issued in connection with Russian Federation Patent Application No. 2000109552.												
	AJ	STN: File Registry printout of Registry Number 162054-19-5 (June 14, 2004).												
200000000000000000000000000000000000000	AK	Abstract of SANTOS et al., "Antinociceptive effect of meloxicam, in neurogenic and inflammatory nociceptive models in Mice," Inflammation Research (1998), 47(7) pages 302-307, Chem. Abst. Vol. 129 (Columbus, OH)												
070300000000000000000000000000000000000	AL	FRÖLICH, J.C., "A classification of NSAIDs according to the relative inhibition of cyclooxygenase isoenzymes," TiPS, January 1997, vol. 18, pages 30-34.												
00000	AM	Abstract of OGINO K. et al., "Evaluation of pharmacological profile of meloxicam as an anti-inflammatroy agent, with particular reference to its relative selectivity for cyclooxygenase-2 over cyclooxygenase-1," Pharmacology 55(1):44-53, July 1997.												
00000000000000000000000000000000000000	AN	Abstract of ISAKSON P. et al., "Discovery of a better aspirin," Advances in Prostaglandin, Thromboxane, & Leukotriene Research 23:49-54, 1995.												
5275D00000000	AO	Abstract of JOUZEAU J.Y. et al., "Cyclo-oxygenase isoenzymes. How recent findings affect thinking about nonsteroidal anti-inflammatory drus," Drugs 53(4):563-82, April 1997.												
*	AP	Abstract of DVORNIK D.M., "Tissue selective inhibition of prostaglandin biosynthesis by etodolac," Journal of Rheumatology, Supplement 47:40-7, February 1997.												
V	AQ	Richy, F., et al., "Time dependent risk of gastrointestinal complications induced by non-steroid anti-inflammatory drug use: a consensus statement using a meta-analytic approach", Ann Rhuem Dis (2004) 64:759-766.												
EXAMINER	_								DATE CONSIDEREI		_ • •			
*EXAMINER: Ir	nitial if re	eference	consid	dered.	whet	her or n	ot cit	ation is in con	formance with MPEP 6	09; Draw line	through citation	if not in		

conformance and not considered. Include copy of this form with next communication to applicant.

NOV 1 9 2007 W

FORM PTO-14 (REV. 7-80)	44 Aray	PADEMARK	√ U.S			MENT C	ATTY. DOCKET I 200.1079CON4	NO.:	SERIAL NO.: 10/056,348					
LIST OF PRIOR ART CITED BY APPLICANT									APPLICANT(S): Ronald M. BURCH, et al.					
(Use several s	heets if r	necessary)					FILING DATE: January 25, 2002		GROUP: 1639					
U.S. PATENT DOCUMENTS														
*EXAMINE R INITIAL		DOCUMENT NUMBER DATE							NAME	CLASS	SUBCLASS FILING DATE			
NAMES OF TAXABLE PARTY.	-BA									THE REAL PROPERTY OF THE PERSON NAMED IN COLUMN TWO IS NOT THE PERSON NAMED IN COLUMN TWO IS NAMED	<u> </u>			
	ВВ	CONTROL OF THE PARTY OF THE PAR	200000000000000000000000000000000000000						The state of the s	AND DESCRIPTION OF THE PARTY OF				
	вс		,	SOSOSOSOSOSOS	NO CONTRACTOR OF THE PARTY OF T	30000000000			THE STREET STREET, STR					
FOREIGN PASSAT DOCUMENTS														
		DOCUMENT NUMBER DATE							COUNTRY CLASS	SUBCLASS	TRANSLATION			
										- AND CONTRACTOR OF CONTRACTOR	200000000000000000000000000000000000000	YES	NO	
	BD										000000000000000000000000000000000000000	000000000000000000000000000000000000000		
STATE OF THE PARTY	BE												SOURCE STATE OF THE STATE OF TH	
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)														
/S.L./	BF	Goodman & Gillman's (1996), The Pharmacological Basis of Therapeutics, 9th Edition, McGraw-Hill, New York, pp. 654-655.												
9900000	BG	Abstract of FLOWER R. J., "New directions in cyclooxygenase research and their implications for NSAID-gastropathy," Italian Journal of Gastroenterology, 28 Suppl. 4:23-7, December 1996.												
000000000000000000000000000000000000000	вн	Abstract of KURUMBAIL R.G. et al., "Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents," Nature, 384(6610):644-8, December 19-26, 1996.												
Baanastooogsa	ВІ	Abstract of HOSIE J. et al., "Meloxicam in osteoarthritis: a 6-month, double-blind comparison with diclofenac sodium," British Journal of Rheumatology, 35 Suppl. 1:39-43, April 1996.												
00000000000	ВЈ	Abstract of PAIRET M. et al., "Distinct isoforms (COX-1 and COX-2) of cyclooxygenase: possible physiological and therapeutic implications," Fundamental & Clinical Pharmacology 10(1):1-17, 1996.												
	ВК	Abstract of MASFERRER J.L. et al, "Cyclooxygenase-2 inhibitors: a new class of anti-inflammatory agents that spare the gastrointestinal tract," Gastroenterology Clinics of North America 25(2):363-72, June 1996.												
30000000000	BL	Abstract of EMERY P., "Clinical implications of selective cycloxygenase-2 inhibiton," Scandinavian Journal of Rheumatology-Supplement 102:23-8, 1996.												
V	ВМ	Van Hecken, Anne, et al., "Comparative Inhibitory Activity of Rofecoxib, Meloxicam, Diclofenac, Ibuprofen, and Naproxen on COX-2 versus COX-1 in Healthy Volunteers", J Clin Pharmacol (2000) 40: 1109-1120.												
\$5000000000000000000000000000000000000	50000000000000000000000000000000000000									04449999999999999999999999999999999999	56320000651900565190066519006651900	003350000000000000000000000000000000000	0000219990002199	
	BN	000000999999	**************************************	0000555000055	20008520000	00001111000000000000000000000000000000	\$5500000000000000000000000000000000000	000055500005	55550005590005590005559000555000055					
905652990565399056529905	BO	000000000000000000000000000000000000000									000000000000000000000000000000000000000	**************************************	pdoor	
EXAMINER	EXAMINER /Sue Liu/								DATE CONSIDERED 06/12/2009					
				•					-					

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.